Moderna Inc
F:0QF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Moderna Inc
F:0QF
|
US |
|
Innventure Inc
NASDAQ:INV
|
US |
Intrinsic Value
The intrinsic value of 
Moderna Inc (0QF) under the Base Case is 17.41 EUR per share.
Compared with the current market price of 177 EUR, the stock appears
Overvalued by 90% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Moderna Does
Moderna is a biotechnology company that develops medicines based on messenger RNA, or mRNA. Instead of making drugs in the traditional way, it designs mRNA instructions that tell the body’s cells to produce specific proteins, which can train the immune system or help treat disease. Its best-known products are vaccines, and its pipeline also includes treatments for infectious diseases, cancer, and rare conditions.
- Headquarters
- United States of America US
- Employees
- 4 700
- IPO date
- Dec 7, 2018
Moderna has no economic moat
Customers can choose among Moderna’s vaccines and competing products from companies such as Pfizer, BioNTech, GSK and Novavax, so rivals can compete for the same sales. Moderna’s technology, patents and product approvals do not prevent alternatives from reaching the market or give the company lasting control over customers or prices.
Read the full moat analysis
Revenue & Expenses Breakdown
Moderna Inc
Earnings Waterfall
Moderna Inc
The intrinsic value for Moderna Inc (0QF) under the Base Case is 17.41 EUR.
Compared with the current market price of 177 EUR, the stock appears Overvalued by 90% .